Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure

Leukemia Research

Volumn 38, Issue 4, 2014, Pages 443-446

  Jaglal, Michael V ^a   Duong, Vu H ^b   Bello, Celeste M ^a   Al Ali, Najla H ^a   Padron, Eric ^a   Fernandez, Hugo F ^a   List, Alan F ^a   Lancet, Jeffrey E ^a   Komrokji, Rami S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Antecedent hematological disorders; Azanucleoside treatment failure; Cladrabine; Secondary AML

Indexed keywords

AZANUCLEOSIDE; CLADRIBINE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE; NUCLEOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTECEDENT HEMATOLOGICAL DISORDERS; AZANUCLEOSIDE TREATMENT FAILURE; CLADRABINE; SECONDARY AML;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; CLADRIBINE; CYTARABINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MITOXANTRONE; MYELODYSPLASTIC SYNDROMES; RECOMBINANT PROTEINS; TREATMENT FAILURE; YOUNG ADULT;

EID: 84897116403     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.12.010     Document Type: Article

References (23)

1. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
2. Font P. Azacitidine for the treatment of patients with acute myeloid leukemia with 20-30% blasts and multilineage dysplasia. Adv Ther 2011, 28(Suppl. 3):1-9.
3. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106:1794-1803.
4. Kantarjian H., O'Brien S., Cortes J., Giles F., Faderl S., Jabbour E., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2006, 106:1090-1098.
5. Gajewski J.L., Ho W.G., Nimer S.D., Hirji K.F., Gekelman L., Jacobs A.D., et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol 1989, 7:1637-1645.
6. Stolzel F., Pfirrmann M., Aulitzky W.E., Kaufmann M., Bodenstein H., Bornhauser M., et al. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia 2011, 25:420-428.
7. Gandhi V., Estey E., Keating M.J., Chucrallah A., Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 1996, 87:256-264.
8. Gandhi V., Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol 1992, 31:11-17.
9. Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 2003, 44:391-409.
10. Kornblau S.M., Gandhi V., Andreeff H.M., Beran M., Kantarjian H.M., Koller C.A., et al. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia 1996, 10:1563-1569.
11. Chow K.U., Boehrer S., Napieralski S., Nowak D., Knau A., Hoelzer D., et al. In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential. Leuk Lymphoma 2003, 44:165-173.
12. Holowiecki J., Grosicki S., Giebel S., Robak T., Kyrcz-Krzemien S., Kuliczkowski K., et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter Randomized Phase III Study. J Clin Oncol 2012, 30:2441-2448.
13. Wierzbowska A., Robak T., Pluta A., Wawrzyniak E., Cebula B., Hołowiecki J., et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol 2008, 80:115-126.
14. Wrzesien-Kus A., Robak T., Wierzbowska A., Lech-Marańda E., Pluta A., Wawrzyniak E., et al. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. Ann Hematol 2005, 84:557-564.
15. Slovak M.L., Kopecky K.J., Cassileth P.A., Harrington D.H., Theil K.S., Mohamed A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
16. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92:2322-2333.
17. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., et al. Revised recommendations of the International Working Group for DIAGNOSIS, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21:4642-4649.
18. Prebet T., Gore S.D., Esterni B., Gardin C., Itzykson R., Thepot S., et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011, 29:3322-3327.
19. Prebet T., Gore S.D., Thepot S., Esterni B., Quesnel B., Beyne Rauzy O., et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol 2012, 157:764-766.
20. Jabbour E., Garcia-Manero G., Batty N., Shan J., O'Brien S., Cortes J., et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010, 116:3830-3834.
21. Rizzieri D.A., O'Brien J.A., Broadwater G., Decastro C.M., Dev P., Diehl L., et al. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. Cancer 2009, 115:2922-2929.
22. Qin T., Castoro R., El Ahdab S., Jelinek J., Wang X., Si J., et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS ONE 2011, 6:e23372.
23. Fernandez H.F., Sun Z., Yao X., Litzow M.R., Luger S.M., Paietta E.M., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361:1249-1259.